

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™

RRID:AB_2726447

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-114-089, RRID:AB_2726447

Antibody Information

URL: http://antibodyregistry.org/AB_2726447

Proper Citation: Miltenyi Biotec Cat# 130-114-089, RRID:AB_2726447

Target Antigen: CD159a (NKG2A)

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-098-809. (RRID:AB_2655385).

Antibody Name: CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™

Description: This monoclonal targets CD159a (NKG2A)

Target Organism: human

Clone ID: clone REA110

Antibody ID: AB_2726447

Vendor: Miltenyi Biotec

Catalog Number: 130-114-089

Record Creation Time: 20250820T040655+0000

Record Last Update: 20250820T180449+0000

Ratings and Alerts

No rating or validation information has been found for CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™.

No alerts have been found for CD159a (NKG2A) Antibody, anti-human, APC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shemesh A, et al. (2022) Diminished cell proliferation promotes natural killer cell adaptive-like phenotype by limiting FcγRI expression. The Journal of experimental medicine, 219(11).

Lee J, et al. (2022) Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. Journal of cancer research and clinical oncology.